More than 70% of breast cancer sufferers are diagnosed as hormone receptor positive and HER2 negative (HR+/HER2-) [1]. Clinical trial data show that a therapy combination with CDK4/6 inhibitors can increase progression-free survival (PFS) and overall survival (OS) [2-5]. This was also the case in the presented case of an 81-year-old female patient with recurrent HR+/HER2- breast carcinoma.
Watch the video to see all details of the case presented by PD Marcus Vetter, MD, Center of Oncology & Hematology, Cantonal Hospital Baselland.
References
1. Blows, F.M., et al, Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. PLoS Med, 2010. 7(5): p. e1000279.
2. Goyal, R.K., et al, Overall survival associated with CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer in the United States: A SEER-Medicare population-based study. Cancer, 2023. 129(7): p. 1051-1063.
3. Goyal, R.K., et al, Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat, 2023. 198(1): p. 159-166.
4. Li, J., et al, Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.Breast Cancer Res Treat, 2020. 180(1): p. 21-32.
5. Elfgen, C. and V. Bjelic-Radisic, Targeted Therapy in HR+ HER2- Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options.Cancers (Basel), 2021. 13(23).
The references are available on request.
The current Ibrance® product information can be found at www.swissmedicinfo.ch.
PP-IBR-CHE-0423 Apr 2023
Post online since 17.05.2023
